Vyluma, Inc.
🇺🇸United States
CHAMP: Study of NVK-002 in Children With Myopia
Phase 3
Completed
- Conditions
- Myopia
- Interventions
- Drug: PlaceboDrug: NVK-002 Concentration 1Drug: NVK-002 Concentration 2
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Vyluma, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT03350620
- Locations
- 🇺🇸
Site #003, Fullerton, California, United States
🇺🇸Site #009, Tucson, Arizona, United States
🇺🇸Site #005, Danbury, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath